



Sample Information

Patient Name: 何慕慕**Gender:** Female**ID No.:** A202482209**History No.:** 19145749**Age:** 72**Ordering Doctor:** DOC3109L 邱昭華**Ordering REQ.:** D59E9E3**Signing in Date:** 2020/07/29**Path No.:** S109-99770**MP No.:** F20050**Assay:** Oncomine Focus Assay**Sample Type:** FFPE**Block No.:** S109-22979A+B**Percentage of tumor cells:** 20%**Note:**

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents

Page

Variants (Exclude variant in Taiwan
BioBank with >1% allele frequency)

2

Biomarker Descriptions

2

Relevant Therapy Summary

3

Report Highlights

1 Relevant Biomarkers

0 Therapies Available

7 Clinical Trials

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	Not detected	NTRK1	Not detected
BRAF	Not detected	NTRK2	Not detected
EGFR	Not detected	NTRK3	Not detected
ERBB2	Not detected	RET	Not detected
KRAS	KRAS amplification	ROS1	Not detected
MET	Not detected		

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	KRAS amplification KRAS proto-oncogene, GTPase	None	None	7

Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO**Tier Reference:** Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.



Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
ALK	p.(D1529E)	c.4587C>G	.	chr2:29416366	100.00%	NM_004304.4	missense	2000
ALK	p.(I1461V)	c.4381A>G	.	chr2:29416572	99.85%	NM_004304.4	missense	2000
ALK	p.(=)	c.3375C>A	.	chr2:29445458	99.95%	NM_004304.4	synonymous	1991
FGFR3	p.(=)	c.1953G>A	.	chr4:1807894	99.65%	NM_000142.4	synonymous	854
PDGFRA	p.(=)	c.939T>G	.	chr4:55133726	48.80%	NM_006206.5	synonymous	1994
PDGFRA	p.(=)	c.1701A>G	.	chr4:55141055	99.80%	NM_006206.5	synonymous	1996
PDGFRA	p.(=)	c.2472C>T	.	chr4:55152040	50.10%	NM_006206.5	synonymous	2000
KIT	p.(=)	c.1638A>G	.	chr4:55593481	48.60%	NM_000222.2	synonymous	1998
FGFR4	p.(P136L)	c.407C>T	.	chr5:176517797	99.60%	NM_213647.2	missense	1999
EGFR	p.(=)	c.2361G>A	.	chr7:55249063	99.75%	NM_005228.4	synonymous	1998
RET	p.(=)	c.2307G>T	.	chr10:43613843	99.95%	NM_020975.4	synonymous	1988

Copy Number Variations

Gene	Locus	Copy Number
KRAS	chr12:25364761	98.55

Biomarker Descriptions

KRAS (KRAS proto-oncogene, GTPase)

Background: The KRAS proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the RAS superfamily which also includes NRAS and HRAS. RAS proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival^{1,2,3}.

Alterations and prevalence: Recurrent mutations in RAS oncogenes cause constitutive activation and are found in 20-30% of cancers. KRAS mutations are observed in up to 10-20% of uterine cancer, 30-35% of lung adenocarcinoma and colorectal cancer, and about 60% of pancreatic cancer⁴. The majority of KRAS mutations consist of point mutations occurring at G12, G13, and Q61^{4,5,6}. Mutations at A59, K117, and A146 have also been observed but are less frequent^{7,8}.

Potential relevance: Currently, no therapies are approved for KRAS aberrations. However, the KRAS G12C inhibitor, sotorasib (AMG 510)⁹, was granted fast track designation (2019) for previously treated non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The EGFR antagonists, cetuximab¹⁰ and panitumumab¹¹, are contraindicated for treatment of colorectal cancer patients with KRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)⁸. Additionally, KRAS mutations are associated with poor prognosis in NSCLC¹².



Relevant Therapy Summary

● In this cancer type ○ In other cancer type ● In this cancer type and other cancer types ⛔ Contraindicated ⚠ Both for use and contraindicated ✕ No evidence

KRAS amplification

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
ASTX029	✕	✕	✕	✕	● (I/II)
mirdametinib, lifirafenib	✕	✕	✕	✕	● (I/II)
RMC-4630, cobimetinib	✕	✕	✕	✕	● (I/II)
BGB-3245	✕	✕	✕	✕	● (I)
LXH254	✕	✕	✕	✕	● (I)
LY3214996, midazolam, abemaciclib, chemotherapy, encorafenib, cetuximab	✕	✕	✕	✕	● (I)
RMC-4630	✕	✕	✕	✕	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:



References

1. Pylayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer*. 2011 Oct 13;11(11):761-74. PMID: 21993244
2. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
3. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
4. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
5. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer*. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
6. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life*. 2014 Oct-Dec;7(4):581-7. PMID: 25713627
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012 May;2(5):401-4. PMID: 22588877
8. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
9. <http://investors.amgen.com/news-releases/news-release-details/amgen-announces-new-clinical-data-evaluating-novel>
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf
12. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829